By Fineline Cube 
AusperBio announced the completion of a USD 120m Series C financing round, a substantial capital raise that will primarily support the Phase III registrational clinical trial and commercialization preparation for its lead candidate AHB-137. Backed by a globally renowned strategic investment institution and a roster of top-tier healthcare funds, the round underscores strong investor conviction in AusperBio’s innovative oligonucleotide platform at a time when the modality is attracting intense global interest.
Financing Overview
| Element | Detail |
|---|---|
| Company | AusperBio |
| Round Type | Series C |
| Size | USD 120m |
| Lead Investor | A globally renowned strategic investment institution |
| New Investor | RA Capital |
| Existing Investors | Hankang Capital, Sherpa Healthcare Partners, InnoPinnacle Fund, Qiming Venture Partners, Yuanbio Venture Capital, DCM VGC |
| Date | 28 Aug 2026 |
Use of Proceeds
- AHB-137 Phase III: Primarily fund the registrational clinical trial for AHB-137, the company’s lead oligonucleotide candidate
- Commercialization Readiness: Prepare commercial infrastructure ahead of potential AHB-137 launch
- AHB-171 Acceleration: Speed development of AHB-171, the next key program in the pipeline
- Combination Therapies: Advance next-generation combination therapy development
- Pipeline Expansion: Further broaden AusperBio’s innovative oligonucleotide product pipeline
Investor Roster & Signaling
| Category | Investors | Signal |
|---|---|---|
| Lead | Globally renowned strategic institution | Strategic validation of platform and lead asset |
| New | RA Capital | Entry of a major global healthcare specialist fund |
| Existing | Hankang Capital, Sherpa Healthcare Partners, InnoPinnacle Fund, Qiming Venture Partners, Yuanbio Venture Capital, DCM VGC | Continued commitment across funding rounds |
The round was led by a globally renowned strategic investment institution, with participation from new investor RA Capital and continued support from existing investors including Hankang Capital, Sherpa Healthcare Partners, InnoPinnacle Fund, Qiming Venture Partners, Yuanbio Venture Capital, and DCM VGC. The participation of RA Capital — one of the world’s most prominent healthcare-focused investment firms — adds international credibility to AusperBio’s oligonucleotide platform as it approaches the registrational stage.
Market Impact & Outlook
- Late-Stage Capital: A USD 120m Series C concentrated on a Phase III registrational trial signals AusperBio is nearing the commercial inflection point for AHB-137
- Oligonucleotide Momentum: The raise rides the global surge in oligonucleotide therapeutics, a modality increasingly favored for its precision and expanding target space
- Commercial Runway: Dedicated commercialization preparation funding indicates the company intends to build its own launch capability rather than rely solely on partnership
- Pipeline Depth: Continued investment in AHB-171 and combination therapies diversifies the company’s value drivers beyond a single lead asset
Forward‑Looking Statements – This brief contains forward-looking statements regarding clinical development, commercialization plans, and pipeline expansion. Financing completion does not guarantee regulatory or commercial outcomes. Not investment advice.-Fineline Info & Tech